BMO Capital Markets reiterated their outperform rating on shares of Mead Johnson Nutrition Co. (NYSE:MJN) in a research note issued to investors on Friday morning. They currently have a $97.00 target price on the stock.
Other analysts have also issued reports about the stock. Deutsche Bank AG set a $88.00 target price on shares of Mead Johnson Nutrition and gave the stock a hold rating in a research note on Sunday, July 24th. Susquehanna restated a hold rating on shares of Mead Johnson Nutrition in a research note on Sunday, July 17th. Credit Agricole SA upgraded shares of Mead Johnson Nutrition from an underperform rating to an outperform rating and set a $96.00 target price on the stock in a research note on Wednesday, August 3rd. Goldman Sachs Group Inc. reiterated a neutral rating and issued a $96.00 price target (up from $91.00) on shares of Mead Johnson Nutrition in a research note on Friday, July 15th. Finally, Bank of America Corp. upgraded shares of Mead Johnson Nutrition from an underperform rating to a neutral rating and set a $93.00 price target on the stock in a research note on Wednesday, July 13th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $94.83.
Mead Johnson Nutrition (NYSE:MJN) opened at 76.78 on Friday. The stock’s 50 day moving average is $82.42 and its 200 day moving average is $84.87. The stock has a market capitalization of $14.18 billion, a price-to-earnings ratio of 28.89 and a beta of 1.17. Mead Johnson Nutrition has a 12-month low of $65.53 and a 12-month high of $94.40.
Mead Johnson Nutrition (NYSE:MJN) last released its earnings results on Thursday, July 28th. The company reported $0.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.10. Mead Johnson Nutrition had a net margin of 13.28% and a negative return on equity of 194.30%. The firm had revenue of $941.50 million for the quarter, compared to analyst estimates of $967.25 million. During the same period in the prior year, the firm earned $0.76 earnings per share. The business’s quarterly revenue was down 8.8% compared to the same quarter last year. Equities research analysts forecast that Mead Johnson Nutrition will post $3.48 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, October 3rd. Stockholders of record on Monday, September 19th will be given a $0.4125 dividend. This represents a $1.65 dividend on an annualized basis and a dividend yield of 2.15%. The ex-dividend date is Thursday, September 15th. Mead Johnson Nutrition’s dividend payout ratio is currently 62.03%.
In related news, Director Kimberly A. Casiano sold 710 shares of Mead Johnson Nutrition stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $89.75, for a total transaction of $63,722.50. Following the completion of the sale, the director now owns 7,110 shares in the company, valued at approximately $638,122.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Graciela Monteagudo sold 45,873 shares of Mead Johnson Nutrition stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $87.64, for a total value of $4,020,309.72. Following the sale, the senior vice president now owns 13,800 shares of the company’s stock, valued at approximately $1,209,432. The disclosure for this sale can be found here. 0.50% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the company. Tobam bought a new stake in Mead Johnson Nutrition during the first quarter worth approximately $3,021,000. CLS Investments LLC bought a new stake in Mead Johnson Nutrition during the first quarter worth approximately $614,000. Ngam Advisors L.P. boosted its stake in Mead Johnson Nutrition by 20.2% in the first quarter. Ngam Advisors L.P. now owns 116,165 shares of the company’s stock worth $9,871,000 after buying an additional 19,556 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Mead Johnson Nutrition during the first quarter valued at approximately $4,605,000. Finally, Apertura Capital LLC boosted its stake in Mead Johnson Nutrition by 146.2% in the first quarter. Apertura Capital LLC now owns 80,000 shares of the company’s stock valued at $6,798,000 after buying an additional 47,500 shares during the period. Hedge funds and other institutional investors own 96.93% of the company’s stock.
About Mead Johnson Nutrition
Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.
Receive News & Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related companies with MarketBeat.com's FREE daily email newsletter.